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Elevated levels of pro-inflammatory biomarkers have been reported in major depressive disorder 
(MDD). The aim of this study is to investigate the plasma levels of interleukin-18 (IL-18), macrophage-
inflammatory protein-1α (MIP-1α), monocyte chemoattractant protein 1 (MCP-1), stromal cell derived 
factor-1 (SDF-1), and regulated upon activation, normal T cell expressed and secreted (RANTES) in 
patients with MDD before and after eight week treatment of fluoxetine hydrochloride in comparison with 
normal controls. All subjects were assessed before and after treatment with the Hamilton Depression 
Rating Scale (HDRS). Our results showed that the symptoms of forty healthy controls and thirty-four 
patients with MDD were correlated with their plasma levels of IL-18, MIP-1α, MCP-1, SDF-1α, and 
RANTES. The levels of all five cytokine of patients with MDD were significantly decreased after 
treatment. However, the levels remained significantly higher than those of the healthy controls 
(p<0.001). In the seven depressed subjects whose HDRS score fell to below seven after antidepressant 
therapy comparing with those subjects whose HDRS score larger than seven, the mean levels of IL-18 
(p=0.01) and SDF-1α(p<0.05) were significantly lower. Conversely, higher levels of cytokines correlated 
with a persistently increased severity of symptoms, as measured by the HDRS scores. In conclusion, 
these findings suggest that MDD is associated with activation of the immune system, and the 
antidepressant effect of fluoxetine may be mediated in part through its anti-inflammatory effects.  
 





Major depressive disorder (MDD), a common and some-
times fatal disorder is one of the leading causes of 
disability worldwide (Lopez et al., 2001). MDD is viewed 
as a disorder that involves abnormalities in the central 
monoaminergic neurotransmitter system and gives rise to 
behavioral changes and alterations in neurohormonal 
pathways. Antidepressants, which largely target mono-
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improvement after treatment with antidepressants occurs 
in less than 70% of depressed patients, and the rate of 
relapse can be as high as 50% (Byrne and Rothschild, 
1998; Nelson, 2003; Connor and Leonard, 1998).  
Recently, it has been suggested that the behavioral 
deficits, central monoamine abnormalities, and activation 
of the hypothalamic-pituitary-adrenal (HPA) axis that are 
observed in MDD are associated with alterations in immune 
function (Maes et al., 1995). There is now evidence that 
MDD is accompanied by an immune response that 
results in an increased production of pro-inflammatory 
cytokines. One study has shown that markers of T cell 





in patients with depression, which suggested that both 
the innate and acquired immune systems are involved in 
the pathogenesis of MDD (Merendino et al., 2002). Kokai 
et al. (2002) found that the mean plasma concentration of  
IL-18 was three-fold higher in non-medicated patients 
with MDD and four-fold higher for patients who had panic 
disorder when compared to normal controls. Piletz et al. 
(2009) reported that patients with MDD had significantly 
higher baseline levels of monocyte chemoattractant protein 
1 (MCP-1), as compared to controls (Piletz et al., 2009). 
Merendino et al. (2004) detected no macrophage-inflam-
matory protein-1α (MIP-1α) expression in normal controls, 
while 20% of patients with depression expressed a 
detectable level of MIP-1α. Stress, which was mimicked 
by the administration of corticosterone in drinking water, 
correlated positively with higher plasma levels of regu-
lated upon activation, normal T cell expressed and 
secreted (RANTES) (Sutcigi et al., 2007). Only rare 
studies have investigated the role of broad spectrum pre-
cytokines such as stromal cell derived factor-1 (SDF-1) 
and RANTES. Even in this limited number of studies, 
conflicting results have also been described. 
Serotonin, or 5-hydroxytryptamine (5-HT) has a well-
described role in the central and peripheral nervous 
system. However, it is also a potent immunomodulator. It 
has been shown to upregulate the production of the pro-
inflammatory cytokine, interleukin-6 (IL-6), and is a potent 
regulator of the function of human dendritic cells (Muller 
et al., 2009). Selective serotonin reuptake inhibitors (SSRI) 
decrease the amount of endothelial adhesion molecule 
expression induced by cytokines, the endothelial 
adhesiveness to monocytes, and circulating levels of 
vascular adhesion molecules (Lekakis et al., 2010). The 
serum concentrations of IL-6, IL-8, IL-10, MIP-1β and 
MCP-1 in women with psychological symptoms such as 
anxiety and mild depression were shown to be decreased 
significantly after they were treated with paroxetine, a 
type of SSRI (Yasui et al., 2009). It is also reported that 
serum il-1β and il-6 did not change significantly after 
intervention with fluoxetine (Jazayeri, 2010). The results 
are inconsistent. 
Few studies have focused on the relationship between 
MDD and IL-18, MCP-1, MIP-1α, SDF-1α, and RANTES; 
we investigate the plasma levels of IL-18, MCP-1, MIP-
1α, SDF-1α, and RANTES in major depression before 
and after 8-week fluoxetine hydrochloride treatment and 
their correlation with symptoms .The goals of this study 
are: (1) To determine the plasma concentrations of IL-18, 
MCP-1, MIP-1α, SDF-1α, and RANTES in a cohort of 
patients with depression; (2) to evaluate whether treat-
ment with a SSRI, fluoxetine hydrochloride, affects the 
pathogenesis of MDD through causing decreased 
circulating levels of these cytokines; (3) whether cases of 
MDD that are refractory to treatment with fluoxetine 
hydrochloride correlate with different degrees of immuno-
activation; and (4) to investigate the correlation of the 
level of these cytokines with  the  severity  of  depression,  












Seventy-four participants (40 healthy control subjects and 34 
subjects with depression) were included in the present study. There 
was no significant difference between the groups with regards to 
age or sex. All of the subjects gave their written informed consent 
prior to commencing the trial. Participants were recruited from the 
outpatient and inpatient of Sir Run Run Shaw Hospital and all of 
them fulfilled the DSM-IV criteria for MDD. Subjects were between 
the ages of 18 and 66 years, with an average of 42.53± 12.1 years 
in patients group and 40.33± 10.1 in control group. 18 males and 16 
females in patients group, 20 males and 20 females in control 
group. Forty healthy volunteers were included in the study as controls. 
The erythrocyte sedimentation rates (ESR) were all normal. 
Computed tomography (CT) or magnetic resonance imaging (MRI) 
scans of the head were normal in all patients with MDD. 
The severity of the depression was quantified by the HDRS on, 
before and after the eight week monotherapy treatment course of 
fluoxetine hydrochloride (fluoxetine; 20 mg/day in first three weeks 
and 40 mg/day in last five weeks). No antidepressant medication 
was taken within the last one year in all subjects. Subjects received 
a thorough psychiatric assessment by a senior psychiatrist before 
and after treatment. The controls also took HDRS. Inter- and intra-
assay coefficients of variation were reliably 10%. All ratings were 
evaluated by a psychiatrist, who was blinded to the immunological 
profiles. All parameters were repeated after treatment with 
fluoxetine. 
The exclusion criteria applied to both the treatment and control 
groups of participants. They included the presence of any additional 
axis I or axis II DSM-IV diagnosis, current pregnancy, acute or 
chronic infections within the past month, dementia, autoimmune, 
allergic, neoplastic or endocrine diseases, and any other acute 
physical disorders, including surgery or myocardial or cerebral 
infarction within the past three months. Patients who had been 
exposed to any drug, which included antidepressants, oral steroids, 
nonsteroidal anti-inflammatory drugs, lithium, immunoregulants, and 
oral contraceptives within the six week period prior to the study 
were also excluded. Additionally, patients who had undergone 
electric shock therapy were excluded. The use of zolpidem was 
permitted for the treatment of insomnia. Healthy volunteers were 
interviewed and those with no lifetime or current diagnosis of any 
psychiatric disorders were included as the control group. 
The current study utilized a prospective control design. The case 





After an overnight fast, blood samples for the cytokine assays were 
collected at between 0700 am to 0800 am from patients with MDD 
and from the healthy controls. Venous blood samples were placed 
on ice immediately and transported to the laboratory. The serum 
samples were then aliquotted and stored at –70°C for later 
measurements of the levels of IL-18, MIP-1α, MCP-1, SDF-1α, and 
RANTES. All immunological parameters were determined by enzyme-
linked immunosorbant assay (ELISA) techniques in accordance 
with the protocols of the manufacturers. After the colorimetric 
reaction was developed, the absorbance at 450 nm was quantified 
by an eight-channel spectrophotometer, and the absorbance 
readings were converted to pg/ml units based upon standard curves 
obtained with recombinant cytokines for each  assay.  If  the  absor-  









MDD before therapy 
(n=34) 
MDD after therapy 
(n=34) 
Total score 3 .04±0.12 24.13 ± 4.39*
#
 10.08 ± 3.03* 
Anxiety/somatization 1.02±0.06 7.68 ± 2.09*
#
 3.33 ± 1.73* 
Dysfunction of cognition 0.71±0.02 2.45 ± 1.83*
#
 0.35 ± 0.66* 
Retardation 0.59±0.04 10.75 ± 3.94*
#
 6.43 ± 3.75* 
Body weight 0.44±0.01 0.65 ± 0.83*
#
 0.25 ± 0.44* 
Insomnia 1.55±0.08 3.98 ± 1.17*
#
 1.05 ± 0.71* 
 
*p<0.01 vs. healthy controls; 
#
 p<0.01 vs. MDD after therapy.  








Healthy controls  
(n=40) 
MDD before treatment  
(n=34) 
MDD after treatment  
(n=34) 
IL-18  55.93 ± 7.98 115.73 ± 12.23*
#
 90.33 ± 2.94* 
MIP-1 α  290.42 ± 33.61 688.75 ± 110.72*
#
 452.36 ± 8.91* 
MCP-1 144.08±19.90 479.18 ± 33.64*
#
 275.84 ± 13.37* 
SDF-1α 1301.33 ± 134.20 2788.00 ± 104.76*
#
 2129.67 ± 81.29* 
RANTES 1.77 ±0.19 3.89 ± 0.09*
#
 2.60 ± 0.18* 
 
*p<0.01 vs. healthy controls; 
#
 p< 0.01 vs. MDD after treatment.  




bance readings exceeded the linear range of  the  standard  curves, 
the ELISA assay was repeated after serial dilution of the super-
natants. Each serum sample was tested in at least two independent 
ELISA experiments, and the data were calculated from the mean of 
between two to four tests for each sample. The same procedures 





Data were analyzed with the Statistical Programme for the Social 
Sciences (SPSS Inc., Ill, USA). The data were expressed as the 
mean ± SD. The lifetime duration of MDD, the duration of this 
current episode of MDD, changes in HDRS before and after treat-
ment, and the immune measurements were analyzed. Pearson’s 
correlation coefficients were calculated to examine the relationship 
of the severity of MDD with the levels of the cytokines. Before and 
after values of the parameters were compared with the use of 
paired samples t tests. The cytokine levels of the control and 
treatment groups before and after treatment were subjected to a 
one-way analysis of variance (ANOVA) followed by an independent 
t test to compare the values in the control and treatment groups. A 






The mean and standard deviation (SD) duration of the 
episode of MDD was 29 ± 13.50 months. The mean age 
of onset of the disease is 40.03±11.78. 17/34 of patients 
were first-onset, another 17/34 of patients were relapsed. 
The HDRS score in the normal controls were all below 
four. The HDRS scores were all ≥17 in the depressed 
subjects, and were ≥24 in 22 of these cases. In 33 cases, 
the HDRS score decreased by more than 50% after 
therapy, and this decrease was more than 75% in one 
case. The HDRS score was ≤7 in eight cases after 
treatment, which is viewed as evidence of clinical 
recovery. The HDRS score showed that anxiety/ somatic-
zation, cognition, retardation, body weight, and sleep 
disorder scores all decreased significantly after treatment 
with fluoxetine (Table 1). The HDRS scores of healthy 
group was 3 .04±0.12 as shown in Table 1.  
The immunological characteristics of the patients with 
MDD and healthy controls and the results of the 
comparisons between the two groups are shown in Table 
2. The ANOVA detected statistical significances among 
the control and the patients pre- and posttreatment of IL-
18 (F[2,105]=36.52, p<0.001), MIP-1α (F[2,105]=26.82, 
p<0.001), MCP-1 (F[2,105]=150.31, p<0.001), SDF-
1α(F[2,105]=140.33, p<0.001), and RANTES (F[2,105]= 
138.30, p<0.001). The differences between the groups 
were confirmed by Duncan's test (p<.001). The mean 
levels of IL-18 (p<0.01), MIP-1α (p<0.01), MCP-1 
(p<0.01), SDF-1α (p<0.01), and RANTES (p<0.01) were 
significantly lower in subjects with MDD after antide- 
pressant therapy than before therapy (Table 2). The 
mean levels of IL-18, MIP-1α, MCP-1, SDF-1α, and 
RANTES remained significantly higher (p<0.001) in 
depressed subjects after antidepressant therapy than in 
normal control subjects (Table 2).  




Table 3. IL-18, MIP-1α, MCP-1, SDF-1α, and RANTES levels in patients of HDRS 






HDRS score ≤7 
(n=7) 
HDRS score>7  
(n=27) 
IL-18  55.93 ± 7.98 75.32 ± 2.52*
#
 92.96 ± 8.47* 
MIP-1 α 290.42 ± 33.61 429.86 ±40.36* 461.81 ± 6.31* 
MCP-1 144.08±19.90 264.87 ± 18.66* 279.96 ± 26.39* 
SDF-1α 1301.33 ± 134.20 1993.67 ±17.62*
#
 2152.67 ± 22.14* 
RANTES 1.77 ±0.19 2.41 ±0.30* 2.74 ± 0.38* 
 
*p<0.01 vs. healthy controls; 
#
 p<0.05 vs. HDRS score >7.  




In the seven cases of patients whose HDRS score was 
≤7 after antidepressant therapy, the mean post-treatment 
levels of IL-18 (p<0.001), MIP-1α (p<0.001), MCP-1 
(p<0.001), SDF-1α (p<0.001), and RANTES (p<0.001) 
were significantly higher than in normal control subjects. 
In these patients, the mean post-treatment levels of IL-18 
(p<0.05) and SDF-1α (p<0.05) were significantly lower 
compared to other depressed subjects whose HDRS 
score >7 after antidepressant therapy (Table 3). 
The levels of each cytokine were correlated with the 
HDRS scores in both groups (p<0.001). The lifetime 
duration of depression was significantly correlated with 
the levels of IL-18 (p<0.01), MIP-1α (p<0.01), SDF-
1α(p<0.01) in patients with MDD before treatment. 
Conversely, the duration of the current episode of MDD 
did not correlate with cytokine level (p>0.05). There was 






Our results showed that the pro-inflammatory cytokines 
and chemokines were significantly higher in patients with 
MDD than those of healthy controls. After antidepressant 
treatment, these cytokines decreased but remained 
higher in patients with MDD than in the healthy controls. 
The levels of each cytokine were significantly correlated 
with the HDRS score. It seems likely that the treatment 
course of fluoxetine hydrochloride might have exerted 
immunomodulatory effects through a consequent decrease 
in the circulating levels of pro-inflammatory cytokines and 
chemokines. However, although the cytokine concentra-
tions decreased after the eight-week course of fluoxetine, 
they remained higher than the healthy controls. The 
refractory nature of symptoms of depression to antide-
pressant treatment, as assessed by the HDRS score, 
appeared to be correlated with high plasma levels of 
cytokines. IL-18 and SDF-1α may be biomarkers of 
antidepressant treatment resistance. 
IL-18, which is a pro-inflammatory cytokine that plays 
an important role in the helper T-cell type 1 response, is a 
new member of the family of cytokines that is known to 
be produced within the brain. MIP-1 is chemoattractive of 
monocyte,and T cell CD4+T cell,CD3+ T cell and memory 
T cell (Taub, 1993). MCP is monocyte chemotactic 
protein. SDF-1 was first described as a factor produced 
by bone marrow stromal cells that induces proliferation of 
B cell progenitors and regulates B cell maturation 
(Nagasawa, 1996). SDF-1 is the unique biological ligand 
for CXCR4. Acting on CXCR4, SDF-1 exerts chemo-
attractant effects on target cells and mediates critical 
retentive functions towards pre-B cells, IL-1, and tumor 
necrosis factor (TNF) which regulate the expression of 
SDF-1 (Fedyk, 2001). SDF-1 induced expression of TNF- 
α, IL-1, RANTES in primary astrocytes (Han, 2001). 
RANTES is a monocyte chemoattractant. Most histone 
may release RANTES induced by IL-1β or TNF-α 
(Marfaing-Koka, 1995). Coexpression of RANTES or 
MCP-1 resulted in the enhanced expression of TNF-α 
(Kim, 1998). These cytokines are chemoattractive of 
different inflammatory cells. So we measured these cyto-
kines to investigate activation of immuno network. 
Merendino et al. (2004) demonstrated that serum IL-18 
levels of patients with MDD were significantly higher than 
those of healthy individuals. These data are consistent 
with our results. Lehto et al. (2010) reported that the MDD 
group had lower levels of MCP-1 than the healthy 
controls. The current study found that levels of IL-18, 
MIP-1α and MCP-1 were higher in patients with MDD 
than in normal controls (Kokai et al., 2002; Piletz et al., 
2009). 
The role of SDF-1α and RANTES in depression is un-
certain. MDD is accompanied by a variety of immuno-
modulatory processes that affect both the innate and the 
acquired immune responses. IL-18, MIP-1α, MCP-1, 
SDF-1α, and RANTES may be potential biomarkers of 
MDD. The plasma level of these cytokines is significantly 
correlated with HDRS. 
Previous investigations have reported increased levels 
of IL-6 during an acute depressive episode, which norma-
lized after an eight-week period of treatment with fluoxetine 
(Maes et al., 1995). Maes et al. (1997) reported that 
treatment with antidepressants had no significant effects 
on serum IL-6, IL-1Ra, CC16 or sCD8. These previous 
study findings have been somewhat  inconsistent.  In  our 




research, cytokines decreased after antidepressant 
treatment. Therefore, we hypothesize that antidepressants 
may alleviate the symptoms of depression by inhibiting 
cytokine secretion from immune cells in vivo. 
In seven cases of patients whose HDRS score was ≤7 
after antidepressant therapy. The mean levels of IL-18 
(p<0.001), MIP-1α (p<0.001), MCP-1 (p<0.001), SDF-1 
(p<0.001), and RANTES (p<0.001) were significantly 
higher than in normal controls. However, the activation of 
the immune system could not be suppressed by 
medication to a normal state after such a short period of 
treatment. This may be one of the reasons why patients 
with MDD need long periods of antidepressant treatment 
to prevent relapses, even after the symptoms are 
relieved. Further research is needed to assess whether 
the immune response, which appears to produce an 
increased level of pro-inflammatory cytokines, will be 
normalized after long periods of treatment with antide-
pressants. If this can be normalized by pharmaceuticals; 
cytokines may become important biomarkers to assist in 
the decisions regarding treatment levels and cessation. 
Clinical improvement after treatment with antide-
pressants generally occurs in less than 70% of depressed 
patients with rates of relapse as high as 50%. Coinci-
dentally, the HDRS score reduced by more than 75% in 
one case and to ≤7 points on the HDRS in eight cases 
after treatment, which was viewed as remission. There is 
a paucity of information with regards to the etiology of 
MDD that is resistant to treatment despite such a high 
occurrence of relapse. Treatment-resistant patients have 
been reported to have elevated plasma levels of IL-6, sIL-
6R, IL-1Ra and sIL-2R (Bosker et al., 2004). In seven 
cases of depressed subjects whose HDRS score was ≤7 
after antidepressant therapy, the mean levels of IL-18 
(p=0.01) and SDF-1α(p<0.05) were significantly lower 
compared to the patients whose HDRS score >7 after 
treatment. The activation of cell-mediated immunity may 
be one probable explanation for decreased response to 
drug therapy in some patients. Consequently, IL-18 and 
SDF-1α may be biomarkers of antidepressant treatment 
resistance.  
A novel psychoneuroimmunological perspective on the 
treatment of depressive illness may be required for the 
successful treatment of this condition, and the current 
prevalent views on depression may need to change. 
Understanding the role that pro-inflammatory mediators 
play in response to drug therapy in depressed patients 
may aid in the explanation of treatment resistance and 
assist in designing more effective pharmacotherapy. 
Immunomodulatory treatment may be a promising target 
for such therapies, and our study sustained this 
perspective. 
We showed in our study that the concentrations of IL-
18, MCP-1, MIP-1α, SDF-1α, and RANTES were 
elevated in patients with MDD. Our results suggest that  
treatment with the SSRI, fluoxetine hydrochloride, may 





kines, at least in part.Treatment resistance of patients 
with MDD to fluoxetine hydrochloride correlated with 
immunoactivation, and IL-18 and SDF-1α may be 
biomarkers of antidepressant treatment resistance. The 
severity of depression, as measured by HDRS, was cor-
related with the level of these cytokines. Yet, these 
cytokines may be not trait-specific; they may be a sign of 
immunoactivation in major depression. 
Administration of proinflammatory cytokines in animals 
induces 'sickness behaviour'' (Alesci et al., 2005) which is 
a pattern of behavioural alterations that is very similar to 
the behavioural symptoms of depression in humans, we 
presume that higher cytokines induce depression. 
Activation of the inflammatory response system 
involves not only specific immune and metabolic altera-
tions but also neuroendocrine changes, such as hyper-
activity of the hypothalamus-pituitary-adrenocortical axis 
and the peripheral and central turnover of 5-HT. The 
central action of cytokines may account for the HPA axis 
hyperactivity that is frequently observed in depressive 
disorders (Wang and Dunn, 1999). Pro-inflammatory 
cytokines may cause HPA axis hyperactivity by disturbing 
the negative feedback inhibition of circulating cortico-
steroids on the HPA axis. With regards to the deficiency 
in 5-HT neurotransmission that is concomitant with MDD, 
cytokines may reduce 5-HT levels by lowering the 
availability of its precursor tryptophan (TRP) through the 
activation of the enzyme that metabolizes TRP, 
indoleamine-2,3-dioxygenase (Brown et al., 1991) Curran 
and O'Connor, (2001) reported that IL-18 impair the 
induction of long-term potentiation (LTP); IL-18 signifi-
cantly depressed the amplitude of pharmacologically 
isolated N-methyl d-aspartate (NMDA) receptor mediated 
fEPSP, IL-18 may affects NMDA-dependent LTP in the 
hippocampus, a main target structure in depression. It 
however, needs further investigation. Although the central 
effects of pro-inflammatory cytokines appear to account 
for most of the symptoms that occur in depression, it 
remains to be established whether cytokines play a 
causal role in depressive illness or represent epipheno-
mena of the disorder without a major causative influence. 
Antidepressants may alleviate depressive symptoms by 
inhibiting cytokine secretion from immune cells in vivo or 
by decreasing the concentration of cytokines in the brain, 
and thereby blocking the action of cytokines in the central 
nervous system (Taler et al., 2008; Zhu et al., 2009). 
Some potential limitations of the current study should 
be noted. Firstly, the duration of treatment was only eight 
weeks. Further research is needed to investigate the 
level of these cytokines after longer periods of therapy. If 
the levels of cytokines continue to decline, it is possible 
that the levels of these cytokines are markers of the 
efficacy of antidepressant therapy and may help to 
determine when to stop treatment for MDD. Secondly, it 
remains unclear whether altered cytokine and chemokine  
levels are responsible for the etiology of depression or 





Thirdly, normal controls did not take the antidepressant, 
and so we do not know whether the cytokine levels would 
have dropped in these patients after the administration of 
fluoxetine. There are also some questions that has not 
being clarified clearly. For example, did depression induced 
higher cytokine levels or did higher cytokines induce 
depression? In addition, a placebo-controlled design would 
be better to show if antidepressants will decrease 
cytokine levels in controls.  Moreover, it would be better 
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MDD, Major depressive disorder; HPA, hypothalamic-
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macrophage-inflammatory protein-1α; RANTES, regulated 
upon activation, normal T cell expressed and secreted; 5-
HT, 5-hydroxytryptamine; IL-6, interleukin-6; SSRI,  
Selective serotonin reuptake inhibitors; HDRS, Hamilton 
depression rating scale; ESR, erythrocyte sedimentation 
rates; ELISA, enzyme-linked immunosorbant assay; TNF, 
tumor necrosis factor; TRP, tryptophan; LTP, long-term 





Alesci S, Martinez PE, Kelkar S, Ilias I, Ronsaville DS, Listwak SJ, 
Ayala AR, Licinio J, Gold HK, Kling MA, Chrousos GP, Gold PW 
(2005). Major depression is associated with significant diurnal 
elevations in plasma interleukin-6 levels, a shift of its circadian rhythm 
and loss of physiological complexity in its secretion: clinical 
implications. J. Clin. Endocrinol. Metab. 90: 2522-2530. 
Bosker FJ, Westerink BH, Cremers TI, Gerrits M, van der Hart MG, 
Kuipers SD, van der Pompe G, ter Horst GJ, den Boer JA, Korf J 
(2004). Future antidepressants: what is in the pipeline and what is 
missing? CNS Drugs, 18: 705-732.  
Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG 
(1991). Implications of interferon-induced tryptophan catabolism in 
cancer, auto-immune diseases and AIDS. Adv. Exp. Med. Biol. 294: 
425-435. 
Byrne SE, Rothschild AJ (1998). Loss of antidepressant efficacy during 
maintenance therapy: possible mechanisms and treatments. J. Clin. 
Psychiatry, 59:279-288.  
Connor TJ, Leonard BE (1998). Depression, stress and immunological 
activation: the role of cytokines in depressive disorders. Life Sci. 62: 
583-606.  
Curran B, O'Connor JJ (2001). The pro-inflammatory cytokine 
interleukin-18 impairs long-term potentiation and NMDA receptor-
mediated transmission in the rat hippocampus in vitro. Neuroscience, 
108: 83-90. 
Kokai  M,  Kashiwamura  S,  Okamura  H,  Ohara  K,  Morita  Y  (2002).  




Plasma interleukin-18 levels in patients with psychiatric disorders. J.  
Immunother. 25: 68-71. 
Lehto SM, Niskanen L, Herzig KH, Tolmunen T, Huotari A, Viinamäki H, 
Koivumaa-Honkanen H, Honkalampi K, Ruotsalainen H, Hintikka J 
(2010). Serum chemokine levels in major depressive disorder. 
Psychoneuroendocrinology, 5: 226-232. 
Lekakis J, Ikonomidis I, Papoutsi Z, Moutsatsou P, Nikolaou M, Parissis 
J, Kremastinos DT (2010). Selective serotonin re-uptake inhibitors 
decrease the cytokine-induced endothelial adhesion molecule 
expression, the endothelial adhesiveness to monocytes and the 
circulating levels of vascular adhesion molecules. Int. J. Cardiol. 139: 
150-158. 
Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ (2006). 
Global and regional burden of disease and risk factors, 2001: 
systematic analysis of population health data. Lancet, 367: 1747-
1757. 
Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E (1997). 
Increased serum IL-6 and IL-1 receptor antagonist concentrations in 
major depression and treatment resistant depression. Cytokine, 9: 
853-858. 
Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, 
Ranjan R, Desnyder R (1995). Increased plasma concentrations of 
interleukin-6, soluble interleukin-6, soluble interleukin-2 and 
transferrin receptor in major depression. J. Affect Disord. 34: 301-
309. 
Maes M, Meltzer HY, Buckley P, Bosmans E (1995). Plasma-soluble 
interleukin-2 and transferrin receptor in schizophrenia and major 
depression. Eur. Arch. Psychiatry Clin. Neurosci. 244: 325-329. 
Merendino RA, Di Pasquale G, De Luca F, Di Pasquale L, Ferlazzo E, 
Martino G, Palumbo MC, Morabito F, Gangemi S (2004). Involvement 
of fractalkine and macrophage inflammatory protein-1 alpha in 
moderate-severe depression. Mediators Inflamm. 13: 205-207. 
Merendino RA, Di Rosa AE, Di Pasquale G, Minciullo PL, Mangraviti C, 
Costantino A, Ruello A, Gangemi S (2002). Interleukin-18 and CD30 
serum levels in patients with moderate-severe depression. Mediators 
Inflamm. 11: 265-267. 
Muller T, Dürk T, Blumenthal B, Grimm M, Cicko S, Panther E, Sorichter 
S, Herouy Y, Di Virgilio F, Ferrari D, Norgauer J, Idzko M (2009). 5-
hydroxytryptamine modulates migration, cytokine and chemokine 
release and T-cell priming capacity of dendritic cells in vitro and in 
vivo. PLoS One, 4: e6453. 
Nelson JC (2003). Managing treatment-resistant major depression. J. 
Clin. Psychiatry, 64: 5-12. 
Piletz JE, Halaris A, Iqbal O, Hoppensteadt D, Fareed J, Zhu H, 
Sinacore J, DevaneCL(2009). Pro-inflammatory biomakers in 
depression: treatment with venlafaxine. World J. Biol Psychiatry, 10: 
313-323.  
Shini S, Kaiser P (2009). Effects of stress, mimicked by administration 
of corticosterone in drinking water, on the expression of chicken 
cytokine and chemokine genes in lymphocytes. Stress, 12: 388-399. 
 Sutcigi L, Oktenli C, Musabak U, Bozkurt A, Cansever A, Uzun O, 
Sanisoglu SY, Yesilova Z, Ozmenler N, Ozsahin A, Sengul A (2007). 
Pro- and anti-inflammatory cytokine balance in major depression: 
effect of sertraline therapy. Clin. Dev. Immunol. 2007: 76396. 
Taler M, Bar M, Korob I, Lomnitski L, Baharav E, Grunbaum-Novak N, 
Weizman A, Gil-Ad I (2008). Evidence for an inhibitory 
immunomodulatory effect of selected antidepressants on rat 
splenocytes: possible relevance to depression and hyperactive-
immune disorders. Int. Immunopharmacol. 8: 526-533. 
Wang J, Dunn AJ (1999). The role of interleukin-6 in the activation of the 
hypothalamo-pituitary-adrenocortical axis and brain indoleamines by 
endotoxin and interleukin-1 beta. Brain Res. 815: 337-348. 
Yasui T, Yamada M, Uemura H, Ueno S, Numata S, Ohmori T, Tsuchiya 
N, Noguchi M, Yuzurihara M, Kase Y, Irahara M (2009). Changes in 
circulating cytokine levels in midlife women with psychological 
symptoms with selective serotonin reuptake inhibitor and Japanese 
traditional medicine. Maturitas, 62: 146-152. 
Zhu J, Wei X, Liu J, Hu Y, Xu J (2009). Interaction of glia activation and 
neurotransmission in hippocampus of neuropathic rats treated with 
mirtazapine. Exp. Clin. Psychopharmacol. 17: 198-203. 
